Intravesical Treatment of Superficial Bladder Cancer

1989 ◽  
pp. 83-93
Author(s):  
W. W. Bonney
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Intravesical Treatment

Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: The impact of previous intravesical treatment

2008 ◽  
Vol 15 (11) ◽  
pp. 976-980 ◽  
Author(s):  
Takehiko Okamura ◽  
Hidetoshi Akita ◽  
Makoto Imura ◽  
Tomoyoshi Kaneko ◽  
Kentaro Mizuno ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Intravesical Treatment ◽  
The Impact

ADJUVANT INTRAVESICAL TREATMENT OF SUPERFICIAL BLADDER CANCER WITH A STANDARDIZED MISTLETOE EXTRACT

2005 ◽  
Vol 174 (1) ◽  
pp. 76-79 ◽  
Author(s):  
URSULA ELSÄSSER-BEILE ◽  
CHRISTIAN LEIBER ◽  
PHILIPP WOLF ◽  
MARTIN LUCHT ◽  
ULRICH MENGS ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Mistletoe Extract ◽  
Intravesical Treatment

Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.

1994 ◽  
Vol 12 (1) ◽  
pp. 7-13 ◽  
Author(s):  
F Boccardo ◽  
D Cannata ◽  
A Rubagotti ◽  
D Guarneri ◽  
A Decensi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Recurrence Rate ◽  
Prophylactic Treatment ◽  
Superficial Bladder Cancer ◽  
Tumor Grade ◽  
Interferon Alfa ◽  
Primary Tumors ◽  
Time To Recurrence ◽  
Intravesical Treatment ◽  
Ifn Treatment

PURPOSE Interferons have shown a definite activity in the intravesical treatment of residual papillary bladder cancer or carcinoma in situ (CIS). The purpose of the present study was to investigate the efficacy of interferon alfa-2b (IFN) as prophylactic treatment of superficial bladder cancer. PATIENTS AND METHODS Two hundred eighty-seven patients with primary pTa G2, pT1 G1 to G2 superficial bladder cancer, following complete transurethral resection (TUR), were randomly allocated to receive intravesical treatment, either with IFN (50 x 10(6) IU) or mitomycin (MIT-C; 40 mg). Drugs were instilled on a weekly basis for a total of 8 weeks. RESULTS MIT-C was superior to IFN treatment with respect to time to recurrence, relative recurrence rate, recurrence rate per 100 patients per month, and recurrence tumor rate per 100 patients per month. This difference was particularly evident in patients with pTa G2 tumors. After multivariate analysis, the number of primary tumors and tumor grade were the best predictors of recurrence, while allocated treatment had only a moderate effect. Intravesical treatment was well tolerated in both arms. However, more local toxicity was experienced by patients treated with MIT-C. On the other hand, fever occurred significantly more frequently in patients treated with IFN. CONCLUSION IFN was less effective, although locally better tolerated, than MIT-C as prophylactic treatment of primary superficial bladder cancer.

Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin

1989 ◽  
Vol 28 (4) ◽  
pp. 287-295 ◽  
Author(s):  
A. P. M. van der Meijden ◽  
P. A. Steerenberg ◽  
I. M. W. van Hoogstraaten ◽  
J. A. Kerckhaert ◽  
L. M. H. Schreinemachers ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Immune Reactions ◽  
Intravesical Treatment

scholarly journals Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation

2018 ◽  
Vol Volume 12 ◽  
pp. 1959-1975 ◽  
Author(s):  
Sinem Karavana ◽  
Zeynep Ay Şenyiğit ◽  
Çağrı Çalışkan ◽  
Gülnur Sevin ◽  
Derya İlem Özdemir ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Ex Vivo ◽  
In Vivo Evaluation ◽  
Gemcitabine Hydrochloride ◽  
Intravesical Treatment
Sign in / Sign up

Export Citation Format

Share Document